#ASH18: Blue­bird and Cel­gene didn’t 'break' their next-gen BC­MA CAR-T, so now they’ll dou­ble down on the dose and root for re­al dura­bil­i­ty

Af­ter the lat­est round of da­ta on bb2121 from blue­bird and Cel­gene left some of the more, um, de­mand­ing an­a­lysts dis­ap­point­ed in terms of dura­bil­i­ty, the ante has been raised sub­stan­tial­ly on the bet they’re mak­ing on their sec­ond-gen CAR-T — bb21217.

De­signed to re­ly more on mem­o­ry cells to amp up the ef­fi­ca­cy — a per­fect­ly rea­son­able the­o­ry that re­lies heav­i­ly on mouse da­ta for its proof-of-con­cept ra­tio­nale — bb21217 de­buted its first da­ta snap­shot at ASH on Sun­day.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER